Prevention of venous thromboembolism: A survey of medical practice;PREVENTION DE LA MALADIE THROMBOEMBOLIQUE VEINEUSE. ENQUETE SUR LES PRATIQUES EN MILIEU MEDICAL HOSPITALIER

Presse Medicale

Volumn 27, Issue 3, 1998, Pages 100-105

  Lepaux, D J ^a,b   Wahl, D ^a   Schuhmacher, H ^a   Nace, L ^a   Angioi, M ^a   Briancon S ^a   Delorme, N ^a   Laurain, M C ^a   Maurer, P ^a   Pinelli, C ^a   Lecompte, T ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b Hopital Marin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A;

ARTICLE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; QUESTIONNAIRE; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT INDICATION; VEIN THROMBOSIS; FRANCE; REVIEW; THROMBOPHLEBITIS;

FRANCE; HUMANS; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0032561917     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Harenberg J, Kallenbach B, Martin U et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thrombosis Research 1990; 59:639-50.
2. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995; 274:335-7.
3. Marik PE, Andrews L, Maini B. Incidence of deep venous thrombosis in ICU patients. Chest 1997; 111:661-4.
4. Coon WW. Epidemiology of veinous thromboembolism. Ann Surg 1977; 186:149-64.
5. Cogo A, Bernardi E, Prandoni P et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154:164-8.
6. Clagett GP, Anderson FA, Heit J, Levine MM, Bronwell Wheeler H. Prevention of venous thromboembolism. 4° ACCP Consensus Conference on Antithrombotic Therapy. Chest 1996; 102:S312-34.
7. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305:567-73.
8. European consensus statement developed at Oakley court hotel ; Windsor, UK, 1-5 November 1991, Med Orion publishing company ed, London 1992.
9. Gallus AS. Medical Patients. In: Hull R, Raskob G, Pineo G eds. Venous Thromboembolism : An Evidence-Based Atlas. Futura ed, New York 1996; 67-73.
10. Couturaud F, Leroyer C, Le Moigne E, Oger E, Mottier D. Prevention de la thrombose veineuse profonde en milieu médical. Presse Med 1996; 25:1935-40.
11. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patient with infectious diseases. Lancet 1996; 347:1357-61.
12. Bergmann JF, Caulin C. Heparin prophylaxis in bedridden patients. Lancet 1996 ; 348:205-6.
13. Cook DJ, Gordon H, Laupacis A, Sackett DL, Goldberg RJ. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 1995; 108:S227-30.
14. Anderson FA, Wheeler HB. Venous thromboembolism. Risk factors and prophylaxis. Clin Chest Med 1995; 16:235-51.
15. Bergmann JF. Prévention de la thrombose veineuse en milieu médical : plaidoyer pour des essais cliniques qui font cruellement défaut. STV 1995; 7:655-7.
16. Maillard C. Les héparines de bas poids moléculaire. Prévention et traitement de la thrombose veineuse profonde. Un entretien avec L. Drouet et J.F. Bergmann. Concours Med 1996; 118:847-51.
17. Levesque H, Courtois H. Prévention de la maladie thromboenbolique veineuse en milieu médical. STV 1997; 9:15-21.
18. Samana MM. Prévention de la maladie veineuse thromboembolique. Rev Prat 1996; 46:1245-53.
19. Bergmann JF, Elkharrat D. Prevention of venous thromboembolic risk in non-surgical patients. Hæmostasis 1996; 26:16-23.
20. Ravaud P, Fourcade A, Durieux P et le Comité scientifique Thrombose de l'AP-HP. Prophylaxie des thomboses veineuse postopératoires : recommandations de l'Assistance publique-Hôpitaux de Paris. STV 1995; 7:119-29.
21. Benattar M, Nguyen P, Viriot E, Saulnier JL. Intervention pharmaceutique sur l'utilisation des héparines de bas poids moléculaire dans un centre hospitalier général. Pharm Hosp Fr 1990; 94:1353-9.
22. Callaert S, Chouaid C, Causse R, Thébault A, et le conseil d'évaluation du Centre hospitalier intercommunal de Créteil. Audit sur la prescription des héparines de bas poids moléculaire. J Pharm Clin 1996; 15:231-4.
23. Demange C, Bourdon JL. Essai d'évaluation de l'utilisation des héparines de bas poids moléculaire dans un centre hospitalier. Pharm Hosp 1996; 31:13-25.
24. Lairy G, Saltiel JC, Berrissoul F, Dupont C. Audit de prescription des héparines de bas poids moléculaire. Pharm Hosp Fr 1993; 105: 181-90.
25. Lepaux DJ, Collard C, Dufay E, Pierson H, Lecompte T, Briançon S. Deep venous thromboembolic disease prophylaxis. Clinical audit Hæmosatasis 1996; 26(S3):364.
26. Spanish Society of Clinical Pharmacology. Multicentre hospital drug utilization study on the prophylaxis of venous thromboembolism. Br J Clin Pharmacol 1994; 37:255-9.
27. Keane MG, Ingenito EP, Godhaber SZ. Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest 1994; 106:13-14.
28. Derry J, Lawrence M, Griew K, Anderson J, Humphreys J, Pandher KS. Auditing audits : the method of Oxfordsire Medical Audit Advisory Group. Br Med J 1991; 303:1247-9.
29. Lepaux DJ, Briançon S, Lecompte T, Delorme N, Pinelli C. Enquête sur les pratiques de prescription du médicament de l'hôpital. Concepts et méthode. Thérapie (sous presse).
30. Bhopal RS, Thomson R. A form to help learn and teach about assessing medical audit papers. Br Med J 1991; 303:1520-2.
31. Walshe K, Coles J. Evaluating audit. Developing a framework. CASPE Research ed, London 1993.
32. Crombie IK, Davies HO. Towards good audit Br J Hosp Med 1992; 48:182-5.
33. Hirsch DR, Goldhaber SZ. Medical patients. In: Goldhaber SZ ed. Prevention of venous thromboembolism. Marcel Dekker Inc Publisher ed, New York 1993: 485-95.